



Cardiac resynchronization therapy: pre 
and post pacemaker implantation issues
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CRT is a class IA indication if the following criteria are fulfi lled: 
Severe symptomatic heart failure (NYHA III or ambulatory NYHA 
IV symptoms) despite optimal medical therapy   
Depressed LV systolic function (LVEF ≤ 35%)
Sinus rhythm with QRS duration ≥ 120ms
This recommendation is based on the results of 8 randomized clinical 
trials comprising 4 017 patients on CRT.(4) All 8 trials have confi rmed 
that CRT improves symptoms, exercise capacity and quality of life. 
Some trials have shown that CRT causes reverse left ventricular (LV) 
remodeling as shown by improvement in echocardiographic parameters 
(LV ejection fraction, LV size and mitral regurgitation). Two trials have 
shown that CRT reduces hospitalizations for heart failure and one trial 
showed CRT improves survival compared to medical therapy alone.
Each criterion warrants further clarifi cation. 
Patients should have severe symptoms (NYHA III, IV) secondary to 
heart failure, usually as a result of ischemic or dilated cardiomyopathy, 
despite optimal medical treatment before being considered for CRT. 
A common diffi culty is distinguishing NYHA II from NYHA III symptoms 
in a patient.  As the NYHA classifi cation is extremely subjective, a better 
objective measurement of effort intolerance is the 6-minute walk test. 
Patients must cover the maximal distance possible in 6 minutes by 
walking and/or running and are allowed to rest if required.  At Groote 
Schuur Hospital, we use a total distance ≥ 420m to correlate with 
NYHA II.  This objective measurement helps to classify symptoms while 
providing a reference for future comparison. CRT for patients with 
NYHA II symptoms and for patients with end-stage heart failure (bail-
out therapy) is under investigation and is currently not recommended.
Patients should be evaluated for CRT when all reversible and 
precipitating causes of heart failure have been addressed.  It may take a 
further few months to titrate heart failure therapy to target doses 
recommended in clinical trials or to maximum doses tolerable by the 
patient. All patients should receive an ACE-I and/or ARB, beta-blocker 
and an aldosterone receptor blocker for prognostic and symptomatic 
benefi t (unless contraindicated). Diuretics should be given for fl uid 
retention and digoxin for additional symptomatic benefi t. It is not 
uncommon for a patient to meet all the criteria for CRT only to 
improve to a NYHA I or II status once lifestyle and precipitating factors 
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Cardiac resynchronization therapy (CRT) 
has been shown to improve clinical outcomes in patients 
with systolic heart failure.  However, up to one-third of 
patients do not benefi t from CRT. Selection of appropriate 
patients with attention to heart failure management and 
optimization of pacemaker settings post-implantation will 
ensure the best chance of a favorable response to CRT. This 
article will review the current indications for CRT and 
provide recommendations regarding optimization and 
follow-up of patients with CRT. SAHeart 2008; 5:156-159
ABSTRACT
CRT PACEM KER 
IMPLANTATION ISSUES
INTRODUCTION
Cardiac resynchronization therapy (CRT) is an effective treatment 
option for selected patients with severe advanced systolic heart 
failure.  
This article will focus on practical management issues pre and post 
pacemaker insertion. Practical issues related to the implantation 
procedure have been reviewed elsewhere.(1)  
PRE-IMPLANTATION ISSUES
Recent guidelines for selecting patients for CRT have been 
published.(2,3)  
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The principle of CRT is to diminish mechanical LV dyssynchrony 
to increase stroke volume. A QRS duration ≥120ms is used as a 
surrogate marker of mechanical dyssynchrony, but is actually a measure 
of electrical dyssynchrony. Electrical dyssynchrony is not always 
accompanied by mechanical dyssynchrony.  The detection of mechanical 
dyssynchrony by echocardiography (see below) in addition to electrical 
dyssynchrony (QRS duration ≥120ms) has been shown to improve the 
sensitivity and specifi city of predicting response to CRT in some but 
not all trials.(4) The defi nition and degree of mechanical dyssynchrony 
required to predict a favourable response to CRT stills needs to be fully 
investigated in clinical trials.(5) Hence, the presence of mechanical LV 
dyssynchrony is not an essential criterion at present. Nevertheless, 
in resource-limited environments, echocardiographic measures of 
mechanical dyssynchrony should form part of the routine workup of a 
patient considered for CRT to best identify suitable candidates.  
The most validated echocardiographic measures of mechanical 
intraventricular dyssynchrony are:
M-Mode of LV in parasternal short-axis view (at papillary muscle 
level): Septal-to-posterior LV wall motion delay ≥ 130ms(6)
Colour-coded TDI (time to peak systolic velocities) of basal-septal 
and lateral segments of LV in 4 chamber view: Septal-to-lateral LV 
delay ≥ 60ms(7)
Mechanical dyssynchrony is similarly not always accompanied by 
electrical dyssynchrony. A recent trial has shown that patients with 
echocardiographic evidence of mechanical dyssynchrony but without 
electrical dyssynchrony (QRS complexes ≤ 120ms) do not benefi t 
from CRT.(8)
Most of the patients in trials had left bundle-branch block and were in 
sinus rhythm.  It is uncertain at present whether patients with atrial 
fi brillation or right bundle-branch block benefi t from CRT.(9,10)  Studies 
show that patients with a combination of right bundle branch block and 
pulmonary hypertension do not benefi t from CRT.
POST-IMPLANTATION ISSUES
Even when patients are selected for CRT on the basis of entry criteria 
used in trials, 20-30% of patients do not respond to CRT. Possible 
reasons for failure to respond include poor patient selection, implanta-
tion factors (e.g. poor lead placement) and post-implantation factors.
Patients should ideally be followed up at 1 month post implantation 
and then at 3-4 monthly intervals because of the higher complication 
rate compared to standard pacemakers. At each visit, patients should 
have a detailed clinical assessment, an ECG done and the pacemaker 
settings checked by a cardiologist and a medical technologist.  The aim 
■
■
of each visit must include standard heart failure management and 
pacemaker interrogation.  Pacemaker interrogation should consist of a 
standard pacemaker check-up (as for single or dual chamber 
pacemakers) and then specifi c CRT parameters should be checked and 
optimized.
Clinical assessment and heart failure management
Patients should be asked about improvement or deterioration in effort 
tolerance and repeated objective 6-minute walk tests performed. All 
randomized trials confi rm a signifi cant improvement in symptoms and 
exercise capacity with CRT. Mean NYHA function class improved by 
almost one class and the mean distance covered during a 6-minute 
walk test increased by a mean of 20% in most randomized trials.(3) Most 
improvement in effort tolerance can be expected to occur in the fi rst 
6 months with sustained long-term benefi t. Clinical examination of 
hemodynamic status may confi rm responsiveness or detect response 
failure early before symptoms arise. 
At each visit, the usual aggravating factors of heart failure should be 
sought for and treated.  As heart failure is a progressive disease, patients 
should be told that compliance on all anti-heart failure medication is 
essential and that medication must be continued even if symptoms 
improve.  Patients must be educated that CRT is complementary and 
not an alternative to good medical therapy.  Adjustments to medications 
may be needed, especially a reduction in diuretics in those who have 
responded well to CRT.
ECG
The current ECG should be compared to previous ECGs as this should 
be the fi rst clue of pacemaker malfunction or that both ventricles are 
not being paced (Figure 1). A biventricular paced rhythm may show 
QRS complexes that are narrower than standard RV apical pacing, a 
change in axis and positive QRS complexes in V1-V3.  
Pacemaker check
Pacemaker evaluation should follow the same systematic steps as for a 
single or dual-chamber pacemaker.  It is inadequate just to check the 
pacing mode and settings and confi rm that the battery is not depleted. 
Pacemaker interrogation includes:
Assessment of the underlying rhythm 
Reviewing stored telemetry data for atrial and ventricular 
arrhythmias 
Performing sensing tests of P and R waves 








LV thresholds are often higher than RV thresholds and doctors must 
ensure that an appropriate safety margin is set to ensure capture. 
Battery life and lead impedances should be documented at each visit to 
monitor for lead fracture and need for box replacement.  
Interrogation of the pacemaker must confi rm that the pacemaker 
is pacing both ventricles. This is unlike the usual backup demand 
pacemaker for most bradycardia indications where the percentage of 
total time paced may range from <1-100% depending on the under-
lying rhythm.  In CRT, pacing is not used as a back-up, but should be 
continuous and pace both ventricles. Without this, synchronization will 
not occur.  Therefore interrogation should show that total ventricular 
pacing is near 100%, a fi gure calculated by summing the total of atrial 
pacing/ventricular pacing plus atrial sensing/ventricular pacing (Figure 2). 
If atrial tachyarrhythmias (e.g. atrial fi brillation) are frequent, it is possible 
that the ventricle will be activated by normal conduction and not via 
the pacemaker which will result in bi-ventricular pacing not being near 
100% and CRT response will be suboptimal. The patient may then 
need an AV node ablation to maximize the ventricular pacing. If there 
are frequent ventricular ectopics, changing the lower ventricular rate 
setting to a higher rate may suppress ventricular ectopy.
Pacemakers must be set in DDD mode with the rate-response turned 
off, i.e. not DDDR mode unless there is chronotropic incompetence. 
This setting will ensure that patients are paced appropriate to their 
physiological requirements and will not lead to unnecessary ventricular 
pacing rates.
Synchronization involves not only synchronizing the left and right 
ventricles but also synchronizing the contraction of the atria and that 
of the ventricles. Current generation pacemakers enable separate 
programming of the delay between the contraction of the left and right 
ventricles (V-V interval) and between the contraction of the atria and 
ventricles (A-V interval). 
To achieve the best cardiac output, which after all is the main indication 
for CRT, the timing of atrial contraction before the occurrence of 
ventricular contraction is critical in order to take full advantage of the 
“atrial kick” and minimize pre-systolic mitral regurgitation and maximize 
stroke volume. Generally, a short A-V time needs to be programmed. 
A: ECG was done after successful implantation of the biventricular AV sequential pacemaker. 
Note the QRS width and QRS axis (minus 105º).
B: ECG was done at follow-up 3 months later. (Please note that the ECGs were done on 
different ECG recording machines and the relative sizes of the pacing spikes are artifactual 
and of no relevance.) This ECG shows biventricular pacing of only every second beat with 
morphology and axis identical to post-implantation. The alternate beats are much wider and 
have an axis of plus 105º. These beats have captured the left ventricle only. This was due to an 
increased right ventricular pacing threshold which happened to result in RV capture of only 
every second beat and failure for the other beats to capture, exposing the lone LV capture. 
This emphasizes the value of ECG in follow-up. This problem was easily corrected by 
pacemaker reprogramming with increased RV lead pacing amplitude.
A B
FIGURE 1: ECGs in CRT: Both 12-lead ECGs are from the same patient with CRT
On interrogation of the biventricular pacemaker, the percentage of pacing must be noted. In 
this example from a Medtronic dual chamber biventricular pacemaker, ventricular pacing 
adds up to 100% of total ventricular beats.  The target is >90%.  Please note that this is what 
the pacemaker “believes” it is doing.  Without additional assessment, it remains unknown 
whether, despite 100% ventricular pacing, biventricular pacing is actually achieved.  The 
patient in Figure 1 had almost 100% ventricular pacing at follow-up pacemaker interrogation 
despite only achieving biventricular capture half the time.
Abbreviations: AS = Atrial sensing, VS = Ventricular sensing, AP = Atrial pacing, 
VP = Ventricular pacing
Initial Interrogation Report 
Pacing (% of total)
AS - VS <0.1%
AS - VP 14.0%
AP - VS 0.0%
AP - VP 86.0%
FIGURE 2: Interrogation of CRT devices
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It is recommended that standard settings be used. At implantation, the 
standard A-V intervals programmed are: paced 110ms, sensed 100ms 
with rate adaptive A-V interval changes turned off. In most patients, this 
empiric setting is suffi cient. In non-responders, however, more careful 
adjustment is appropriate to set the AV intervals to maximize stroke 
volume. This is a time-consuming process done with echocardiography 
by maximizing LV stroke volume (LV stroke volume = cross sectional 
area of LVOT X velocity time integral) while testing a series of different 
AV intervals.  
The other adjustment that may improve response is the interventricular 
pacing interval or V-V time. At implantation, the standard V-V interval is 
set at 0ms.  In poor or non-responders, the V-V interval can be adjusted 
to obtain maximal electrical synchrony between the 2 ventricles.  This 
can be done by adjusting the V-V interval (e.g. making the LV pacing 
earlier than the RV in 20ms intervals) while observing the width of the 
paced QRS complex. Theoretically, the narrowest paced QRS should 
correlate with the least electrical dyssynchrony. Although this is relatively 
simple to do and does not require echocardiography, this method of 
optimization has not been shown to improve clinical outcomes. 
Alternatively, stroke volume can be measured as described above while 
the V-V intervals are adjusted to maximize aortic stroke volume. 
In studies, the highest stroke volume is usually obtained by pacing the 
LV fi rst (usually 40ms).   It must be re-iterated that the above adjustments 
are extremely labour intensive and time consuming with little proven 
clinical benefi t. Standard settings are usually adequate unless the 
clinical response is poor. In these non-responders, echocardiographic 
optimization can be performed.(11) It is unclear whether A-V optimization 
should preceed V-V optimization or vice versa. More recently, some 
pacemakers offer quick automated optimization using intracardiac 
electrograms from the atria, RV and LV to optimize A-V and V-V delays. 
Although this method has a close correlation with stroke volume 
derived from aortic VTI with echocardiography, clinical outcome data is 
lacking.(12)
Echo follow-up
Ideally all patients should have a repeat echocardiogram after 
implantation (usually at 3-6 months). Results of several trials indicate 
that CRT causes reverse LV remodeling, decreases LV end-systolic and 
end-diastolic volumes and increases LVEF. Randomized trials typically 
demonstrated a mean 15% absolute reduction in LV end-diastolic 
diameter and up to a mean 6% increase in LVEF following CRT.(3) These 
effects were greater in patients with non-ischemic than in those with 
ischemic heart disease. The CARE-HF study confi rmed that the reverse 
remodeling was sustained up to 18 months.(13)  
Patient advice
Driving is usually permitted 1 week after device implantation.  Patients 
should be counseled about electromagnetic interference as a potential 
cause of pacemaker malfunction.  Sources of in-hospital electromagnetic 
interference include electrocautery, lithotripsy, radiofrequency ablation 
and magnetic resonance imaging. Out-of-hospital sources, including 
mobile telephones and electronic surveillance equipment, are much 
less of a problem. 
CONCLUSIONS
CRT is an important treatment option in some patients with advanced 
systolic heart failure.  Selection of appropriate patients with attention 
to heart failure management and optimization of pacemaker settings 
post-implantation will ensure the best chance of a favourable response 
to CRT.
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